Australian cancer researchers will receive a significant financial boost from $9.01 million in funding through Cancer Australia’s Priority-driven Collaborative Cancer Research Scheme (PdCCRS).
The PdCCRS is an annual research grants scheme developed by Cancer Australia that brings together different funders of cancer research and provides a national approach to funding in identified priority areas.
This year, the Australian Government, through Cancer Australia, will invest $5.35 million, with funding partners contributing $3.66 million, to fund the successful grant applications.
Cancer Australia CEO Professor Helen Zorbas said the scheme brings together government and non-government organisations to maximise investment in cancer research at a national level.
“The PdCCRS fosters collaboration between cancer researchers which builds Australia’s cancer research capacity, impacts on practice and policy, and improves outcomes for people affected by cancer.” Professor Zorbas said.
“Research to receive funding this year includes investigations into novel markers for detection and diagnosis of cancer, and research into improved cancer treatments.”
Since its inception in 2007, 265 grants totalling $92 million have been funded through the scheme.
Twenty-three cancer research projects this year will be funded or co-funded by Cancer Australia, Cancer Council Australia, Cancer Council NSW, Cure Cancer Australia Foundation, National Breast Cancer Foundation, Prostate Cancer Foundation of Australia, and The Kids’ Cancer Project.
The PdCCRS is conducted by Cancer Australia in collaboration with The National Health and Medical Research Council (NHMRC).
-
Further details of successful grant applications in the 2014 round of Cancer Australia’s PdCCRS
Successful applicants of the 2014 round of PdCCRS:
Batra, Jyotsna
Queensland University of Technology
Identification of HNF1B downstream targets as novel cancer therapeutic targets and biomarkers
Co-funded by Cure Cancer Australia Foundation and Cancer Australia
Butler, Lisa
University of Adelaide
Molecular hallmarks of heat shock protein 90 inhibition in prostate cancer
Funded by Cancer Australia
Campbell, Ian
Peter MacCallum Cancer Centre
Improving population based mammographic screening
Funded by National Breast Cancer Foundation
Davis, Ian
Monash University
Pain Free TRUS B: A placebo-controlled, randomised trial of methoxyflurane to reduce the discomfort of prostate biopsy
Co-funded by Prostate Cancer Foundation of Australia and Cancer Australia
Day, Bryan
QIMR Berghofer Medical Research Institute
Eph Receptor tyrosine kinases as targets for therapy in paediatric medulloblastoma
Co-funded by The Kids’ Cancer Project, Cure Cancer Australia Foundation and Cancer Australia
Fogarty, Gerald
University of Sydney
ANZMTG 01.07 Whole Brain Radiotherapy (WBRT) following local treatment of intracranial metastases of melanoma – a randomised phase III trial.
Funded by Cancer Australia
Foley, Bree
Telethon Institute for Child Health Research
Enhancing NK cell mediated anti-tumour responses
Funded by Cure Cancer Australia Foundation
George, Jacob
Westmead Hospital, Sydney
HCC Outcomes mitigation and disease PrEvention through Clinical Partnerships (HOPE)
Funded by Cancer Council NSW
Guimaraes, Fernando
QIMR Berghofer Medical Research Institute
Targeting suppressive TGF-βR and A2AR pathways in natural killer (NK) cells: Enhancing the anti-metastatic response against breast cancer progression.
Co-funded by Cure Cancer Australia Foundation and Cancer Australia
Guitera, Pascale
University of Sydney
ANZMTG 01.12 RADICAL – RADiotherapy (RT) or Imiquimod (ImiQ) in Complex lentigo mALigna (LM)
Funded by Cancer Australia
Hannan, Ross
University of Melbourne
Novel combination therapies targeting the ribosome to treat prostate cancer (PC)
Funded by Cancer Australia
Haydon, Andrew
The Alfred Hospital, Melbourne
SCOT - Short Course Oncology Therapy - A study of adjuvant chemotherapy in colorectal cancer
Funded by Cancer Australia
Hollier, Brett
Queensland University of Technology
Targeting neuropilin-1 to inhibit prostate cancer metastasis and therapy resistance
Co-funded by Cure Cancer Australia Foundation, Prostate Cancer Foundation of Australia and Cancer Australia
Huang, Chen-Yu
University of Sydney
Real-time Six Degree of Freedom Tumour Motion Management in Cancer Radiotherapy
Funded by Cancer Australia
Hutchinson, Andrew
University of Technology Sydney
Preclinical assessment of phosphatidylserine targeting mAbs in multiple myeloma
Funded by Cure Cancer Australia Foundation
Keall, Paul
University of Sydney
SPARK: STEREOTACTIC PROSTATE ADAPTIVE RADIOTHERAPY UTILISING KILOVOLTAGE INTRAFRACTION MONITORING
Co-funded by Prostate Cancer Foundation of Australia and Cancer Australia
Kovacevic, Zaklina
University of Sydney
Molecular functions of the iron regulated Metastasis Suppressor, NDRG1 and its potential as a molecular target
Co-funded by Cure Cancer Australia Foundation and Cancer Australia
Lakhani, Sunil
University of Queensland
Unravelling clinical and molecular heterogeneity in metaplastic breast cancer – a unique ‘stem cell like’ malignancy
Funded by National Breast Cancer Foundation
Mileshkin, Linda
Peter MacCallum Cancer Centre
RECUPERATE: can REaltime molecular profiling in Carcinoma of Unknown Primary improvE tReAtment ouTcomEs?
Funded by Cancer Council Australia
Nowak, Anna
University of Western Australia
Phase III trial of Concurrent & Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma.
Funded by Cancer Australia
O’Brien, Ricky
University of Sydney
Reducing Thoracic Imaging Dose and Improving Image Quality in Radiotherapy Treatments
Funded Cancer Australia
Pollock, Pamela
Evaluating combination therapies in FGFR2 mutant EC cell lines and patient-derived xenograft models
Funded by Cancer Australia – gynaecological cancers program
Siva, Shankar
Peter MacCallum Cancer Centre
Investigating the safety and efficacy, quality of life, cost-efficiency and immune potential of high precision lung radiotherapy
Funded by Cancer Australia – lung cancer program
Media contact:
Simon Thomas, Cancer Australia: (02) 9357 6401 or 0438 209 833